Fourteen years of profound experience in the analytical services to support product development from feasibility stage to Phase III. Analytical method development, method validation, ICH-based stability studies, identification of drug degradation pathway, degradation product characterization, product specifications. Author and editor of CMC sections of drug application filings with FDA and HealthCanada.